{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"title":"Events"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}],"title":"Censored"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"PFS for the comparison B vs A will be measured from the date of randomization disclosure to the date of first observation of PD in second line therapy, or death from any cause as an event. Subjects who have not progressed or who withdraw from the study will be censored at the time of the last complete disease assessment. All subjects who were lost to FU will also be censored at the time of last complete disease assessment","groups":[{"description":"Pd","id":"OG000","title":"Arm A"},{"description":"CPd","id":"OG001","title":"Arm B"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ITT","reportingStatus":"POSTED","timeFrame":"57 months","title":"Progression Free-survival 2(PFS2)","type":"SECONDARY","unitOfMeasure":"Participants"}